SandboxAlonso: Difference between revisions
Jump to navigation
Jump to search
Line 61: | Line 61: | ||
{{familytree/start}} | {{familytree/start}} | ||
{{familytree | | | | | | | | | | A01 | | | | | {{familytree | | | | | | | | | | A01 | | | | | A01=What the specific subtype according to the specific histological characteristics of the tumor?}} | ||
{{familytree | | | | | |,|-|-|-|-|^|-|-|-|-|.| | | |}} | {{familytree | | | | | |,|-|-|-|-|^|-|-|-|-|.| | | |}} | ||
{{familytree | | | | | B01 | | | | | | | | B02 | | | B01=<div style="float: left; text-align: left; width: 14em; padding:1em;"> | {{familytree | | | | | B01 | | | | | | | | B02 | | | B01=<div style="float: left; text-align: left; width: 14em; padding:1em;"> | ||
Line 70: | Line 70: | ||
{{familytree | | | | | C01 | | | | | | | | C02 | | | C01=Perform specific EGFR and ALK mutation testing: What is the specific mutation?|C02=Is the patient smoker or former smoker?}} | {{familytree | | | | | C01 | | | | | | | | C02 | | | C01=Perform specific EGFR and ALK mutation testing: What is the specific mutation?|C02=Is the patient smoker or former smoker?}} | ||
{{familytree | |,|-|-|-|+|-|-|-|.| | | | | |!| | |}} | {{familytree | |,|-|-|-|+|-|-|-|.| | | | | |!| | |}} | ||
{{familytree | D01 | | D02 | | D03 | | | | D04 | | | {{familytree | D01 | | D02 | | D03 | | | | D04 | | | D01=Sensitizing EGFR mutation|D02=ALK mutation|D03=Negative EGFR and ALK|D04=Click here for the squamous cell carcinoma specific treatment}} | ||
{{familytree | |!| | | |!| | | |!| | | | |}} | {{familytree | |!| | | |!| | | |!| | | | |}} | ||
{{familytree | E01 | | E02 | | E03 | | | {{familytree | E01 | | E02 | | E03 | | | E01=Click here for the sensitizing EGFR mutation specific treatment|E02=Click here for the specific therapy for the ALK mutation specific treatment|E03=Click here for the treatment of negative sensitizing EGFR and ALK mutation metastatic disease}} | ||
{{familytree/end}} | {{familytree/end}} |
Revision as of 14:31, 20 June 2014
Stage IV
Is pleural o pericardial effusion present (suggestive of M1a) or are findings suggestive of systemic metastasis (M1b) present? | |||||||||||||||||||||||||||||||||||||||||||||
M1a | M1b | ||||||||||||||||||||||||||||||||||||||||||||
Perform the following tests:
| Perform the following tests:
| ||||||||||||||||||||||||||||||||||||||||||||
Is the liquid extracted positive for malignant cells? | Are findings suggestive of adrenal metastasis or brain metastasis? | ||||||||||||||||||||||||||||||||||||||||||||
Yes | No | Adrenal | Brain | ||||||||||||||||||||||||||||||||||||||||||
Local therapy
PLUS | Perform a needle aspiration biopsy for metastasis confirmation | Surgical resection + adjuvant radiation therapy Radiation therapy alone:
PLUS | |||||||||||||||||||||||||||||||||||||||||||
If the lung disease is curable, administer therapy for the local adrenal lesion:
OR | What is the TN stage of the lung tumor? | ||||||||||||||||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||||||||||||||||
| Administer therapy for metastatic disease in case of not curable lung lesions (click here for the treatment of local and systemic metastasis and neoplastic recurrence) | ||||||||||||||||||||||||||||||||||||||||||||
Metastatic disease
What the specific subtype according to the specific histological characteristics of the tumor? | |||||||||||||||||||||||||||||||||||||||
| Squamous cell carcinoma | ||||||||||||||||||||||||||||||||||||||
Perform specific EGFR and ALK mutation testing: What is the specific mutation? | Is the patient smoker or former smoker? | ||||||||||||||||||||||||||||||||||||||
Sensitizing EGFR mutation | ALK mutation | Negative EGFR and ALK | Click here for the squamous cell carcinoma specific treatment | ||||||||||||||||||||||||||||||||||||
Click here for the sensitizing EGFR mutation specific treatment | Click here for the specific therapy for the ALK mutation specific treatment | Click here for the treatment of negative sensitizing EGFR and ALK mutation metastatic disease | |||||||||||||||||||||||||||||||||||||